4-(3-溴苯基)-2-吡咯烷酮 | 1105187-44-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 4-(3-溴苯基)-2-吡咯烷酮
• 英文名称: 4-(3-bromophenyl)pyrrolidin-2-one
• CAS: 1105187-44-7
• 化学式: C₁₀H₁₀BrNO
• 分子量: 240.099
• InChiKey: OKCQAQCUYZLTCI-UHFFFAOYSA-N

物化性质

• 沸点：
  405.7±45.0 °C(Predicted)
• 密度：
  1.485

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317

反应信息

• 作为反应物：
  描述：

  4-(3-溴苯基)-2-吡咯烷酮 在 盐酸 作用下， 以 水 为溶剂， 反应 16.0h， 以100%的产率得到4-amino-3-(3-bromophenyl)butanoic acid hydrochloride
  参考文献：
  名称：

  WO2020002325A5

  摘要：

  公开号：

  WO2020002325A5
• 作为产物：
  描述：

  (Z)-ethyl 3-(3-bromophenyl)acrylate 在 铁粉 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 生成 4-(3-溴苯基)-2-吡咯烷酮
  参考文献：
  名称：

  Synthesis and Preclinical Evaluation of an ¹⁸F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [¹⁸F]SynVesT-2

  摘要：

  Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new F-18-labeled SV2A PET imaging probe, [F-18]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.

  DOI：

  10.1021/acschemneuro.9b00618

文献信息

• COMPOUNDS
  申请人：Spero Therapeutics, Inc.

  公开号：EP3810633A1

  公开（公告）日：2021-04-28
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：SPERO THERAPEUTICS INC

  公开号：WO2020002325A1

  公开（公告）日：2020-01-02

  The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: formula (I) wherein -R15 is a group: formula (II) and -R16 is hydrogen; -R17 is hydrogen; -L- is a covalent bond or methylene; and -Ar is optionally substituted aryl. The groups -X-, -R1, -R2, -R3, -R4, and -R8 are as defined herein.
• Synthesis and Preclinical Evaluation of an ¹⁸F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [¹⁸F]SynVesT-2
  作者：Zhengxin Cai、Songye Li、Wenjie Zhang、Richard Pracitto、Xiaoai Wu、Evan Baum、Sjoerd J. Finnema、Daniel Holden、Takuya Toyonaga、Shu-fei Lin、Marcel Lindemann、Anupama Shirali、David C. Labaree、Jim Ropchan、Nabeel Nabulsi、Richard E. Carson、Yiyun Huang

  DOI：10.1021/acschemneuro.9b00618

  日期：2020.2.19

  Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new F-18-labeled SV2A PET imaging probe, [F-18]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.
• WO2020002325A5
  申请人：——

  公开号：WO2020002325A5

  公开（公告）日：2022-07-07